In a report released today, Difei Yang from Mizuho Securities maintained a Buy rating on Viveve Medical Inc (VIVE), with a price target of $4. The company’s shares closed on Friday at $2.32.
Yang said:
“We believe recent FDA letters will ultimately play to Viveve’s advantage as competitors exit the space and Viveve continues to advance robust clinical trials which are expected to readout in mid-2019 to early 2020. If successful, we believe SUI could be a multi-billion dollar market opportunity for VIVE.”
According to TipRanks.com, Yang is a 5-star analyst with an average return of 18.1% and a 45.8% success rate. Yang covers the Healthcare sector, focusing on stocks such as Alder Biopharmaceuticals, Audentes Therapeutics, and Revance Therapeutics.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Viveve Medical Inc with a $6 average price target, representing a 158.6% upside. In a report issued on November 9, Maxim Group also maintained a Buy rating on the stock with a $6 price target.
.
See today’s analyst top recommended stocks >>
The company has a one-year high of $5.40 and a one-year low of $1.60. Currently, Viveve Medical Inc has an average volume of 239.9K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Viveve Medical, Inc. engages in the provision of health products. Its activities include development and distribution of women’s health solutions. Its products include non-surgical, non-ablative medical device that remodels collagen and restores vaginal tissue. The company was founded on March 3, 1987 and is headquartered Englewood, CO.
